Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy

Journal of the National Cancer Institute

Volumn 106, Issue 11, 2014, Pages

  Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR;

APOPTOSIS; CLINICAL TRIAL (TOPIC); ESTROGEN ACTIVITY; HUMAN; LONG TERM CARE; MICROMETASTASIS; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TUMOR GROWTH; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; MENOPAUSE; METABOLISM; MIDDLE AGED; PROCEDURES; SIGNAL TRANSDUCTION; TIME FACTOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP2D6; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN; TIME FACTORS;

EID: 84984998149     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju296     Document Type: Review

References (112)

1. Jordan VC, Dix, CJ, Allen, KE. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon S, Jones S, eds. Adjuvant Therapy of Cancer II. New York, NY: Grune & Stratton Inc.; 1979:19-26.
2. Jordan VC, Allen KE. Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer. 1980;16(2):239-251.
3. Jordan VC. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat. 1983;3 Suppl:S73-S86.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451-1467.
5. Hubay CA, Pearson OH, Marshall JS, et al. Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial. Breast Cancer Res Treat. 1981;1(1):77-82.
6. Ribeiro G, Palmer MK. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J (Clin Res Ed). 1983;286(6368):827-830.
7. Ludwig, Group BCS. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet. 1984;323:1256-1260.
8. Cummings FJ, Gray R, Davis TE, et al. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo. Ann Intern Med. 1985;103(3):324-329.
9. Rose C, Thorpe SM, Andersen KW, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet. 1985;1(8419):16-19.
10. Ribeiro G, Swindell R. The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma-7-yr results. Eur J Cancer Clin Oncol. 1985;21(8):897-900.
11. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years. Lancet. 1983;1(8319):257-261.
12. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years. Lancet. 1985;1(8433):836-840.
13. Fisher B, Brown A, Wolmark N, et al. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 1987;106(5):649-654.
14. Scottish Cancer Trials Office (MRC). Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Edinburgh. Lancet. 1987;2(8552):171-175.
15. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88(21):1529-1542.
16. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816.
17. The aTTom Collaborative Group. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31(18 Suppl).
18. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev. 1984;36(4):245-276.
19. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981;304(1):16-21.
20. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
21. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patientlevel meta-Analysis of randomised trials. Lancet. 2011;378(9793):771-784.
22. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652-1662.
23. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272-282.
24. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99(4):283-290.
25. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.
26. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-1141.
27. Fan P, Agboke FA, McDaniel RE, et al. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur J Cancer. 2014;50(2):457-468.
28. McDaniel RE, Maximov PY, Jordan VC. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story. Vitam Horm. 2013;93:1-49.
29. Brauch H, Schwab M. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. Br J Clin Pharmacol. 2014;77(4):695-703.
30. Province MA, Goetz MP, Brauch H, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-Analysis of heterogeneous study populations. Clin Pharmacol Ther. 2014;95(2):216-227.
31. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell. 2004;5(3):207-213.
32. Jordan VC. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer-survival or death? J Clin Oncol. 2008;26(18):3073-3082.
33. McCowan C, Wang S, Thompson AM, et al. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013;109(5):1172-1180.
34. Chlebowski RT, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila). 2014;7(4):378-387.
35. Jordan VC, Ford LG. Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis. Cancer Prev Res (Phila). 2011;4(5):633-637.
36. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25(2):127-205.
37. Lien EA, Ueland PM, Solheim E, et al. Determination of tamoxifen and four metabolites in serum by low-dispersion liquid chromatography. Clin Chem. 1987;33(9):1608-1614.
38. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 1991;51(18):4837-4844.
39. Daniel P, Gaskell SJ, Bishop H, et al. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur J Cancer Clin Oncol. 1981;17(11):1183-1189.
40. Jordan VC, Fritz NF, Tormey DC. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987;47(2):624-630.
41. MacCallum J, Cummings J, Dixon JM, et al. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer. 2000;82(10):1629-1635.
42. Gjerde J, Gandini S, Guerrieri-Gonzaga A, et al. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat. 2012;134(2):693-700.
43. Jordan VC, Collins MM, Rowsby L, et al. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol. 1977;75(2):305-316.
44. Jordan VC, Dix CJ, Naylor KE, et al. Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. J Toxicol Environ Health. 1978;4(2-3):363-390.
45. Allen KE, Clark ER, Jordan VC. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-Activity relationships. Br J Pharmacol. 1980;71(1):83-91.
46. Borgna JL, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem. 1981;256(2):859-868.
47. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem. 2003;46(6):883-908.
48. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem. 2003;46(7):1081-1111.
49. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 1990;50(14):4177-4189.
50. Lien EA, Solheim E, Kvinnsland S, et al. Identification of 4-hydroxy-Ndesmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 1988;48(8):2304-2308.
51. Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989;49(8):2175-2183.
52. Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004;85(2):151-159.
53. Lim YC, Desta Z, Flockhart DA, et al. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005;55(5):471-478.
54. Lim YC, Li L, Desta Z, et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther. 2006;318(2):503-512.
55. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-2741.
56. Jordan VC, Gosden B. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology. 1983;113(2):463-468.
57. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 1987;47(15):4020-4024.
58. Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm. 2000;57(18):1669-1675; quiz 1676-1678.
59. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696-706.
60. Liu H, Lee ES, Gajdos C, et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst. 2003;95(21):1586-1597.
61. Balaburski GM, Dardes RC, Johnson M, et al. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol. 2010;37(2):387-398.
62. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003;9(6):1980-1989.
63. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25(2):270-275.
64. Ward HW. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1973;1(5844):13-14.
65. Morgan LR Jr., Schein PS, Woolley PV, et al. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat Rep. 1976;60(10):1437-1443.
66. Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer. 2008;44(1):30-38.
67. Osborne CK, Coronado EB, Robinson JP. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol. 1987;23(8):1189-1196.
68. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988;48(18):5183-5187.
69. Gottardis MM, Wagner RJ, Borden EC, et al. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res. 1989;49(17):4765-4769.
70. Wolf DM, Langan-Fahey SM, Parker CJ, et al. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst. 1993;85(10):806-812.
71. Gottardis MM, Jiang SY, Jeng MH, et al. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989;49(15):4090-4093.
72. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20(16):3386-3395.
73. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20(16):3396-3403.
74. Wolf DM, Jordan VC. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res. 1993;127:23-33.
75. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000;6(5):2028-2036.
76. Haddow A, Watkinson JM, Paterson E, et al. Influence of synthetic oestrogens on advanced malignant disease. Br Med J. 1944;2(4368):393-398.
77. Haddow A. David A. Karnofsky memorial lecture. Thoughts on chemical therapy. Cancer. 1970;26(4):737-754.
78. Stoll B. Palliation by castration or hormone ablation. In: Stoll BA, (ed). Breast Cancer Management Early and Late. London, UK: William Herman Medical Books Ltd; 1977:135-149.
79. Obiorah I, Jordan VC. 2012 NAMS/PFIZER-Wulf H. Utian endowed lecture. The scientific rationale for a delay after menopause in the use of conjugated equine estrogens in postmenopausal women that causes a reduction in breast cancer incidence and mortality. Menopause. 2013;20(4):372-382.
80. Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001;67(2):111-116.
81. Lonning PE. Additive endocrine therapy for advanced breast cancer-back to the future. Acta Oncol. 2009;48(8):1092-1101.
82. Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitorresistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009;302(7):774-780.
83. Wolf DM, Jordan VC. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat. 1994;31(1):117-127.
84. Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat. 1994;31(1):129-138.
85. Liu H, Lee ES, Deb Los Reyes A, et al. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res. 2001;61(9):3632-3639.
86. Li S, Shen D, Shao J, et al. Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. Cell Rep. 2013;4(6):1116-1130.
87. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al. D538G Mutation in Estrogen Receptor-Alpha: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer. Cancer Res. 2013;73(23):6856-6864.
88. Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439-1445.
89. Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-1451.
90. Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of Constitutively Active Estrogen Receptor-Alpha Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2014;20(7):1757-1767.
91. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
92. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305-1314.
93. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476-486.
94. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A. 1986;83(8):2496-2500.
95. Levenson AS, Jordan VC. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res. 1997;57(15):3071-3078.
96. Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res. 2009;69(4):1243-1254.
97. Song RX, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 2001;93(22):1714-1723.
98. Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiolinduced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005;97(23):1746-1759.
99. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427.
100. Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103(4):296-305.
101. Ariazi E, Cunliffe H, Lewis-Wambi JS, et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A. 2011;108(47):18879-18886.
102. Fan P, Griffith OL, Agboke FA, et al. c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res. 2013;73(14):4510-4520.
103. Sengupta S, Obiorah I, Maximov PY, et al. Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013;169(1):167-178.
104. Obiorah I, Sengupta S, Curpan R, et al. Defining the conformation of the estrogen receptor complex that controls estrogen induced apoptosis in breast cancer. Molecular Pharmacology. 2014;85:789-799.
105. Obiorah IE, Jordan VC. Differences in the Rate of Oestrogen-induced Apoptosis in Breast Cancer by Estradiol and the Triphenylethylene Bisphenol. Br J Pharmacol. 2014;171(17):4062-4072
106. Lundgren K, Brown M, Pineda S, et al. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res. 2012;14(2):R57.
107. Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;14(11):1067-1076.
108. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22):2783-2790.
109. Jordan VC. A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? Menopause. 2014;In press.
110. Jordan VC. Timing is key to avoid the bad and enhance the good of soy supplements. J Natl Cancer Inst. 2014:In press.
111. Murdter TE, Schroth W, Bacchus-Gerybadze L, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89(5):708-717.
112. Maximov PY, McDaniel RE, Fernandes DJ, et al. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. British Journal of Pharmacology. 2014;In press.